O'Donoghue DP - Search Results

1

The relationship between cyclooxygenase-2 expression and colorectal cancer.

Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE. Sheehan KM, et al. JAMA. 1999 Oct 6;282(13):1254-7. doi: 10.1001/jama.282.13.1254. JAMA. 1999. PMID: 10517428

2

Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.

Sheehan KM, O'Donovan DG, Fitzmaurice G, O'Grady A, O'Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE. Sheehan KM, et al. Eur J Gastroenterol Hepatol. 2003 Apr;15(4):375-80. doi: 10.1097/00042737-200304000-00007. Eur J Gastroenterol Hepatol. 2003. PMID: 12655257

3

Peritoneal involvement in stage II colon cancer.

Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K. Lennon AM, et al. Am J Clin Pathol. 2003 Jan;119(1):108-13. doi: 10.1309/J6BD-TWM2-M792-TN2V. Am J Clin Pathol. 2003. PMID: 12520705

4

Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.

Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Troy AM, et al. Eur J Cancer. 2004 Jul;40(10):1610-6. doi: 10.1016/j.ejca.2004.03.011. Eur J Cancer. 2004. PMID: 15196548

5

Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis.

Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP, Parfrey NA. Leahy DT, et al. J Pathol. 1996 Dec;180(4):364-70. doi: 10.1002/(SICI)1096-9896(199612)180:4<364::AID-PATH683>3.0.CO;2-0. J Pathol. 1996. PMID: 9014855

6

Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K. Skelly MM, et al. Clin Cancer Res. 1997 Oct;3(10):1837-40. Clin Cancer Res. 1997. PMID: 9815571

7

Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Mulcahy HE, et al. Lancet. 1994 Aug 27;344(8922):583-4. doi: 10.1016/s0140-6736(94)91968-2. Lancet. 1994. PMID: 7914963

8

Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.

Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Wang LM, et al. Am J Surg Pathol. 2009 Jan;33(1):134-41. doi: 10.1097/PAS.0b013e318184cd55. Am J Surg Pathol. 2009. PMID: 18971777

9

High clusterin expression correlates with a poor outcome in stage II colorectal cancers.

Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, O'Sullivan J. Kevans D, et al. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):393-9. doi: 10.1158/1055-9965.EPI-08-0302. Epub 2009 Jan 20. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19155441

10

Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer.

Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, O'Donoghue D, Hyland J, Sheahan K, Mulcahy H, O'Sullivan J. Sullivan S, et al. Int J Cancer. 2009 Jul 1;125(1):54-61. doi: 10.1002/ijc.24275. Int J Cancer. 2009. PMID: 19291794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters